Compare SCLX & MYPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | MYPS |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | 34 | 543 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 55.5M |
| IPO Year | N/A | N/A |
| Metric | SCLX | MYPS |
|---|---|---|
| Price | $6.48 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 92.4K | ★ 505.1K |
| Earning Date | 04-10-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $122.52 | N/A |
| Revenue Next Year | $186.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.09 | $0.40 |
| 52 Week High | $34.27 | $1.60 |
| Indicator | SCLX | MYPS |
|---|---|---|
| Relative Strength Index (RSI) | 39.05 | 52.65 |
| Support Level | $6.20 | $0.42 |
| Resistance Level | $8.18 | $0.51 |
| Average True Range (ATR) | 1.38 | 0.05 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 1.16 | 44.75 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Companies games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.